Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.O)

ALNY.O on Nasdaq

50.13USD
12:51pm EDT
Change (% chg)

$0.62 (+1.26%)
Prev Close
$49.51
Open
$50.36
Day's High
$50.72
Day's Low
$49.40
Volume
148,512
Avg. Vol
979,505
52-wk High
$80.11
52-wk Low
$31.38

ALNY.O

Chart for ALNY.O

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.90
Market Cap(Mil.): $4,260.46
Shares Outstanding(Mil.): 86.05
Dividend: --
Yield (%): --

Financials

  ALNY.O Industry Sector
P/E (TTM): -- 57.54 29.95
EPS (TTM): -4.79 -- --
ROI: -33.40 -0.41 13.21
ROE: -37.54 6.21 14.38

BRIEF-Invitae Corp announces a program in partnership with Alnylam Pharmaceuticals

* Announced a program in partnership with Alnylam Pharmaceuticals to provide genetic testing for hereditary ATTR (HATTR) amyloidosis Source text for Eikon: Further company coverage:

Apr 03 2017

BRIEF-Alnylam receives European Medicines Agency prime designation for accelerated assessment of givosiran

* Alnylam receives European Medicines Agency prime designation for accelerated assessment of givosiran, an investigational rnai therapeutic for the treatment of acute hepatic porphyrias

Mar 01 2017

BRIEF-Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent period activity

* Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent period activity

Feb 08 2017

BRIEF-ALNYLAM PRESENTS NEW DATA ON FITUSIRAN AT EAHAD

* ALNYLAM PHARMACEUTICALS INC - ANNOUNCED NEW RESULTS FROM AN EXPLORATORY ANALYSIS OF ITS PHASE 1 STUDY WITH FITUSIRAN

Feb 02 2017

BRIEF-The Medicines Company, Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran

* The Medicines Company and Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran (formerly PCSK9si)

Nov 15 2016

BRIEF-Alnylam pharmaceuticals announces Sanofi Genzyme opt-in decision

* Alnylam Pharmaceuticals announces Sanofi Genzyme opt-in decision for co-development and co-commercialization of fitusiran in hemophilia and rare bleeding disorders

Nov 14 2016

BRIEF-Alnylam Pharmaceuticals, Medicines Co announce publication of Phase 1 Clinical Data with Inclisiran

* Results from study showed doses 300 mg significantly reduced pcsk9 and ldl cholesterol for at least 6 months

Nov 13 2016

BRIEF-Alnylam Pharmaceuticals reports Q3 loss per share $1.21 including items

* Alnylam pharmaceuticals reports third quarter 2016 financial results and highlights recent period activity

Nov 02 2016

More From Around the Web

Earnings vs. Estimates